Combined treatment with selinexor and dexamethasone shows encouraging activity in patients with highly refractory multiple myeloma, according to a phase 2 trial
Introduction : Despite unprecedented advances in the treatment of multiple myeloma (MM), almost all patients develop a disease that is resistant to the five most commonly used and active anti-MM agents
Oral selinexor-dexamethasone for triple-class refractory Multiple myeloma (MM) patients with triple- and penta-refractory disease have a poor survival and limited treatment options
The first-in-class selective inhibitor of nuclear export, or SINE, compound, selinexor (Xpovio), in combination with dexamethasone, was granted FDA approval in 2019 for heavily pretreated patients with multiple myeloma, and subsequent regulatory actions have made this therapy available to a greater share of patients
The combination of once weekly (QW) selinexor, QW bortezomib, and dexamethasone (XVd) is FDA approved for previously treated MM
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy
Multiple myeloma in combination with dexamethasone (Sd): Starting dose: 80 mg on Days 1 and 3 of each week (160 mg total per week) Survival of patients with multiple myeloma (MM) has improved significantly with the introduction of new agents over the past 20 years
Selinexor (SEL) is a novel, oral, first-in-class selective inhibitor of